Using big data analysis, Vision genomics focuses on Age-related macular degeneration (AMD) and has developed the AMD Medicine drug discovery platform with personalized medicine. The platform includes databases of gene expression, genetic and epigenetic data, and drugs with known molecular targets. Advanced algorithms screen for drugs that minimize the difference between healthy and disease states, targeting signaling pathways that are pathologically activated or down-regulated while accounting for pharmacogenomic effects. The company was founded by scientists who have engaged in projects related to the interplay of inter-cellular signaling pathways in age-related diseases and progeroid syndromes, identifying AMD as a disease model in which interventions may be effective.